The extended use of deflux (dextranomer/hyaluronic acid) in pediatric urology.
The use of injectable bulking agents into the submucosal layer of the pediatric urinary tract continues to grow. Treatment strategies for vesicoureteral reflux and urinary incontinence have changed with the introduction of dextranomer/hyaluronic acid as a minimally invasive option. Socially and medically debilitating conditions requiring major surgical reconstruction and hospitalization in the past have now been replaced by outpatient endoscopic procedures. As experience has been gained, broader uses of this agent have been applied to more complex etiologies of reflux and incontinence.
Dean
Gregory E
GE
Temple University Children's Medical Center, 3509 North Broad Street, Philadelphia, PA 19140, USA. gedean951@hotmail.com
Doumanian
Leo R
LR
D001672:Biocompatible Materials / Q000008:administration & dosage*; D002648:Child; D003432:Cross-Linking Reagents / Q000008:administration & dosage*; D003911:Dextrans / Q000008:administration & dosage*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D007267:Injections; D014549:Urinary Incontinence / Q000209:etiology / Q000628:therapy*; D013520:Urologic Surgical Procedures; D014718:Vesico-Ureteral Reflux / Q000209:etiology / Q000628:therapy*
D001672:Biocompatible Materials; D003432:Cross-Linking Reagents; D003911:Dextrans; C094535:deflux; D006820:Hyaluronic Acid